Psychosis associated with acute recreational drug toxicity: a European case series

Odd Martin Vallsnes1,2*, Alison M. Dines3, David M. Wood3,4, Christopher Yates5, Fridtjof Heyerdahl6, Knut Erik Hovda6, Isabelle Giraudon7, Euro-DEN Research Group

Abstract

Background: Psychosis can be associated with acute recreational drug and novel psychoactive substance (NPS) toxicity. However, there is limited data available on how common this is and which drugs are most frequently implicated. We describe a European case series of psychosis associated with acute recreational drug toxicity, and estimate the frequency of psychosis for different recreational drugs.

Methods: The European Drug Emergencies Network (Euro-DEN) collects data on presentations to Emergency Departments (EDs) with acute recreational drug and NPS toxicity at 16 centres in ten countries. Euro-DEN data from October 2013 through September 2014 was retrospectively searched, and cases with psychosis were included. The proportion of cases with psychosis per drug was calculated in the searched Euro-DEN dataset.

Results: Psychosis was present in 348 (6.3 %) of 5529 cases. The median (interquartile range) age was 29 (24-38) years, 276 (79.3 %) were male and 114 (32.8 %) were admitted to psychiatric ward. The drugs most commonly reported were cannabis in 90 (25.9 %) cases, amphetamine in 87 (25.0 %) and cocaine in 56 (16.1 %). More than one drug was taken in 189 (54.3 %) cases. Psychosis was frequent in those ED presentations involving tryptamines (4/7; 57.1 %), methylenedioxypyrovalerone (MDPV) (6/22; 27.3 %), methylphenidate (6/26; 23.1 %), lysergic acid diethylamide (LSD) (18/86; 20.9 %), psilocybe mushrooms (3/16; 18.8 %), synthetic cannabinoid receptor agonists (4/26; 15.4 %) and amphetamine (87/593; 14.7 %), but less common in those involving mephedrone (14/245; 5.7 %), methylenedioxymethamphetamine (MDMA) (20/461; 4.3 %) and methedrone (3/92; 3.3 %). Amphetamine was the most frequent drug associated with psychosis when only one agent was reported, with psychosis occurring in 32.4 % of these presentations.

Conclusion: The frequency of psychosis in acute recreational drug toxicity varies considerably between drugs, but is a major problem in amphetamine poisoning. In rapidly changing drug markets and patterns of use, the Euro-DEN sentinel network contributes to measuring the scale of drug-related harms in Europe beyond other more established indicators.

Keywords: Psychosis, Psychostimulants, Hallucinogens, Novel psychoactive substances, Amphetamine, Recreational drugs, Acute poisoning, Acute toxicity, Substance use disorders

Abbreviations: 6-APB, 6-(2-aminopropyl)benzofuran; AMT, Alpha-methyltryptamine; D2PM, Diphenylprolinol;
Background
Acute psychosis is a serious medical condition associated with significant morbidity [1]. Use of classic sympathomimetic drugs like amphetamine, methamphetamine and cocaine can induce acute psychosis [2–4]. Whilst the prevalence of psychosis in the community has been estimated at about 0.5 % [5, 6], the prevalence of drug induced psychosis among regular drug users has been reported to be in the range of 8–46 % for amphetamine [2] and 7–86 % for cocaine [3]. The wide ranges are probably due to variations in methods of data collection and the populations studied [2, 3]. Recent decades have seen an increased potency of cannabis preparations [7–9], carrying an increased risk of psychosis [10]. Though most drug induced psychoses resolve within a few days, as many as 8–27 % have been reported to persist for more than one month [11–13].

Over the last decade there has been an increase in the availability and use of a multitude of novel psychoactive substances (NPS), with 101 new substances reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2014 [8]. These NPS encompass a variety of drug classes, including the cathinones, phenethylamines, tryptamines, piperazines and synthetic cannabinoid receptor agonists (SCRA) [14–17]. There have been numerous reports of acute NPS toxicity associated with psychosis, involving several different drugs, among them methylenedioxypyrovalerone (MDPV), mephedrone, alpha-methyltryptamine (AMT), 6-(2-amino propyl)benzofuran (6-APB), diphenylprolinol (D2PM), and SCRA [17–28]. However, there is limited data available on how common psychosis is in patients presenting with acute recreational drug or NPS toxicity and which drugs are most frequently implicated.

The European Drug Emergencies Network (Euro-DEN) is a European Commission funded project which collected data on presentations to Emergency Departments (EDs) with acute recreational drug and NPS toxicity in 16 sentinel centres in ten European countries [29]. This has been continued as the Euro-DEN Plus network following completion of the initial project, with the aim of increasing the number of centres and coverage across Europe.

Methods
The aim of this study was to describe the cases of psychosis associated with acute recreational drug and NPS toxicity reported in the first year of the Euro-DEN project and to estimate the psychosis rate in acute toxicity presentations with different recreational drugs and NPS.

We have previously described the Euro-DEN methodology in detail [29]. The participating centres were mainly hospital emergency departments, some were specialist toxicology units, and one was a primary care emergency outpatient clinic. For the remainder of this article we will use the term recreational drugs to encompass both classical recreational drugs and NPS.

Inclusion
Patients presenting to a participating Euro-DEN centre with symptoms and/or signs consistent with acute recreational drug toxicity and/or directly related to recreational drug use were included in Euro-DEN; presentations with isolated ethanol intoxication were excluded. Recreational drugs were defined as any psychoactive compound taken for recreational rather than for medical or work purposes or deliberate self-harm (this included classical recreational drugs, NPS and prescription medicines); the drug(s) involved in the presentation were based on the patient’s self report and/or the clinical assessment of the treating physician. For each included case we collected a minimum data set of pre-defined demographic, clinical and outcome variables from information in the patients’ medical records. For this study, Euro-DEN data from October 2013 through September 2014 were retrospectively searched, and all presentations with psychosis as a clinical feature were included.

Psychosis was one of the pre-defined clinical features collected in the minimum data set. Psychosis was defined as any episode of delusions, transient or persistent, accompanied by confusion, hallucinations and lack of insight, based on the assessment of the treating clinician as documented in the patient’s notes.

Data extraction
The data extracted for this study were: age and gender, drugs taken, clinical observations at presentation (temperature, heart rate, blood pressure, respiratory rate, conscious level, blood glucose), clinical features (psychosis, hallucinations, agitation, anxiety, hyperthermia), treatment and outcome (disposition from the ED, length of hospital stay and death in hospital).
Outcome measures
We calculated the proportion of presentations with psychosis for each drug amongst all presentations in the Euro-DEN dataset where the drug was reported, whether as a sole drug or in combination with others. We also calculated the odds ratio (OR) for presenting with psychosis for each drug.

Ethics
The study was done in accordance with the Helsinki declaration. Each centre obtained appropriate ethical approval to collect the data from their institution. Written consent from the patients was not necessary, as no data other than that collected as part of the routine clinical examination was being used for the project.

Statistics
Pearson’s chi-square test or Fisher’s exact test (for expected cell values five or less) were used to compare frequencies. T-test or Mann-Whitney U-test were used in comparisons of continuous variables. Logistic regression analyses were used to estimate the association between psychosis and different recreational drugs. For each drug the patients presenting without psychosis were defined as the reference group (OR = 1). In the multivariate analyses the odds ratios for psychosis being a clinical feature associated with a drug were adjusted for other drugs reported (Table 3). Analyses were done in IBM SPSS version 21 (IBM Corp.) and in an online calculator from EpiTools epidemiological calculators (http://epitools.ausvet.com.au) [30].

Results
Over the 12 month period there were 5529 cases with acute recreational drug toxicity reported to the Euro-DEN project from the participating centres, and psychosis was recorded as a clinical feature in 348 (6.3 %). Table 1 lists the number of presentations with psychosis at each of the participating centres; the proportion of presentations with psychosis varied from 3.0 to 16.3 %.

Amongst the patients presenting with psychosis, the median (interquartile range (IQR)) age was 29 (24-38) years, and 276 (79.3 %) were male (Table 2). In addition to psychosis, 63.2 % had agitation, and 43.7 % had hallucinations (Table 2). The drugs most commonly reported in the presentations with psychosis were cannabis in 90 (25.9 % of the psychosis presentations), amphetamine in 87 (25.0 %) and cocaine in 56 (16.1 %). More than one drug was taken in 189 (54.3 %) of the presentations with psychosis, including 105 (30.2 %) cases in which ethanol was co-ingested.

The strongest associations with psychosis were found for tryptamines (psychosis in 57.1 % of presentations; adjusted OR 12.4), MDPV (27.3 %; adjusted OR 6.5), methylphenidate (23.1 %; adjusted OR 3.9), lysergic acid diethylamide (LSD) (20.9 %; adjusted OR 3.1), amphetamine (14.7 %; adjusted OR 3.0), and methamphetamine (11.3 %; adjusted OR 2.3) (Table 3).

In the 159 single agent cases, the largest proportions of presentations with psychosis were found for tryptamines (2/2; 100 %), MDPV (2/2;100 %), methylphenidate (2/5; 40.0 %), amphetamine (44/136; 32.4 %), and LSD (7/27; 25.9 %) (Table 3). For benzodiazepines the proportion of presentations with psychosis was small (3.4 %), and nearly all (94.1 %) benzodiazepine cases with psychosis were in combination with other drugs.

Treatment was required in 192 (55.2 %) of the presentations with psychosis, including sedation in 154 (44.3 %). The most common sedatives/antipsychotics given were benzo diazepines in 127 (36.5 %) cases, olanzapine in 27 (7.8 %), haloperidol in 26 (7.5 %) and propofol in 14 (4.0 %). The median length of stay in hospital was 5.1 hours (IQR 2.3-13.6). In 132 (37.9 %) cases the patient was medically discharged from the ED, a significantly lower proportion than the 58.2 % among those without psychosis (p < 0.001) (Table 2). In 114 (32.8 %) cases the patient was admitted to a psychiatric ward, compared to 3.3 % among those without psychosis (p < 0.001). There was no difference in the proportions admitted to critical care.

---

### Table 1

| Centre, Country       | Total presentations n | Presentations with psychosis n (%) |
|-----------------------|-----------------------|------------------------------------|
| Barcelona, Spain      | 199                   | 22 (11.1)                          |
| Basel, Switzerland    | 216                   | 12 (5.6)                           |
| Copenhagen, Denmark   | 183                   | 6 (3.3)                            |
| Drogheda, Ireland     | 36                    | 4 (11.1)                           |
| Dublin, Ireland       | 526                   | 19 (3.6)                           |
| Gdansk, Poland        | 144                   | 17 (11.8)                          |
| London KCH, UK        | 422                   | 13 (3.1)                           |
| London STH, UK        | 956                   | 29 (3.0)                           |
| Mallorca, Spain       | 181                   | 12 (6.6)                           |
| Munich, Germany       | 214                   | 22 (10.3)                          |
| Oslo OAEOC, Norway    | 1478                  | 113 (7.6)                          |
| Oslo OUH, Norway      | 199                   | 9 (4.5)                            |
| Paris, France         | 454                   | 42 (9.3)                           |
| Pärnu, Estonia        | 15                    | 1 (6.7)                            |
| Tallinn, Estonia      | 104                   | 17 (16.3)                          |
| York, UK              | 202                   | 10 (5.0)                           |
| Total                 | 5529                  | 348 (6.3)                          |

**KCH**: King’s College Hospital NHS Foundation Trust
**OAEOC**: Oslo Accident and Emergency Outpatient Clinic
**OUH**: Oslo University Hospital
**STH**: St Thomas’ Hospital (Guy’s and St Thomas’ NHS Foundation Trust)
**UK**: United Kingdom of Great Britain and Northern Ireland
Psychosis was a clinical feature in 6.3% of this European case series of 5529 presentations to an ED with acute recreational drug toxicity. The association with psychosis varied considerably between drugs. Not surprisingly, the associations were strongest for hallucinogens and some central stimulants. Overall, cannabis, amphetamine and cocaine were the drugs most commonly involved in presentations with psychosis. Amphetamine was the drug most frequently involved in single agent presentations, with 32.4% single agent amphetamine cases presenting with psychosis. Amongst the NPS, psychosis was rare in presentations involving mephedrone and methedrone, but occurred more frequently with tryptamines, MDPV, methylphenidate and the SCRAs.

Among the patients presenting with recreational drug toxicity and psychosis, 63.2% were agitated and/or aggressive (compared to 24.1% of those without psychosis), 43.7% had hallucinations (compared to 4.5%), and 32.8% were admitted to a psychiatric ward (compared to 3.3%), indicating that this is a group of patients with substantial resource implications. Furthermore, acute

| Table 2 Presentations with psychosis – demographics, clinical data and disposition from the ED |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Presentations with psychosis | Presentations without psychosis | Presentations with psychosis | Presentations without psychosis |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| n (%) median (IQR) mean (SD) | n (%) median (IQR) mean (SD) | p-value | n (%) median (IQR) mean (SD) |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Age | Total 29 years (24-38) 31 years (24-39) | 0.077b | 0.077b |
| Males | 276 (79.3) 29 years (24-38) | 0.041b | 0.041b |
| Females | 72 (20.7) 26.5 years (22-39) | 0.675b | 0.675b |
| Observations at presentation | Respiratory rate 18 /min (5) 16 /min (5) | <0.001 | <0.001 |
| Heart rate 100 /min (22) 91 /min (24) | <0.001 | <0.001 |
| Systolic blood pressure 131 mmHg (20) 125 mmHg (21) | <0.001 | <0.001 |
| Diastolic blood pressure 80 mmHg (16) 77 mmHg (16) | 0.004 | 0.004 |
| Temperature 36.7 °C (0.8) 36.3 °C (0.9) | <0.001 | <0.001 |
| Blood glucose 5.7 mmol/L (5.1-6.9) 5.6 mmol/L (4.9-6.7) | 0.079 | 0.079 |
| Conscious level | Alert (GCS 15) 203 (58.3) 2564 (49.5) | 0.002 | 0.002 |
| Drowsy (GCS 8-14) 122 (35.1) 2013 (38.9) | 0.002 | 0.002 |
| Comatose (GCS ≤ 7) 9 (2.6) 448 (8.6) | <0.001 | <0.001 |
| Not recorded 14 (4.0) 156 (3.0) | 0.369 | 0.369 |
| Clinical features | Hallucinations 152 (43.7) 232 (4.5) | <0.001 | <0.001 |
| Agitation/aggression 220 (63.2) 1247 (24.1) | <0.001 | <0.001 |
| Anxiety 129 (37.1) 911 (17.6) | <0.001 | <0.001 |
| Hyperthermia 7 (2.0) 67 (1.3) | 0.375 | 0.375 |
| Disposition from ED | Medically discharged 132 (37.9) 3016 (58.2) | <0.001 | <0.001 |
| Self discharge 50 (14.4) 906 (17.5) | 0.157 | 0.157 |
| Admitted critical care 14 (4.0) 318 (6.1) | 0.140 | 0.140 |
| Admitted psychiatric ward 114 (32.8) 170 (3.3) | <0.001 | <0.001 |
| Admitted other 38 (10.9) 739 (14.3) | 0.097 | 0.097 |
| Death - 16 (0.3) 0.601 | 0.601 | 0.601 |
| Unknown - 16 (0.3) 0.601 | 0.601 | 0.601 |
| Length of stay in hospital | 5.1 hours (2.3-13.6) 4.6 hours (2.5-9.7) | 0.176 | 0.176 |
| Total | 348 (100) 5181 (100) | | | |

aNo significant difference in gender proportions between presentations with and without psychosis (p = 0.091)
bP-value for comparison of age

ED: emergency department; GCS: Glasgow Coma Scale; IQR: interquartile range; SD: standard deviation
| Drug                        | All presentations where the drug was reported | Crude                                | Adjusted                               | Presentations where the drug was the single agent reported |
|-----------------------------|-----------------------------------------------|--------------------------------------|----------------------------------------|-------------------------------------------------------------|
|                             | Total n (%) With psychosis n (%)              | Odds ratio 95 % CI p-value            | Odds ratio 95 % CI p-value              | Total n (%) With psychosis n (%)                             |
| Tryptamines                 | 7 (0.1) 4 (57.1)                              | 20.1 4.5 - 90.0 < 0.001              | **12.4** 2.3 - 65.2 0.003              | 2 (0.1) 2 (100)                                             |
| MDPV                        | 22 (0.4) 6 (27.3)                             | 5.7 2.2 - 14.6 < 0.001               | **6.5** 2.2 - 19.2 0.001               | 2 (0.1) 2 (100)                                             |
| Methylenediphendate         | 26 (0.5) 6 (23.1)                             | 4.5 1.8 - 11.3 0.001                 | **3.9** 1.5 - 10.2 0.006               | 5 (0.2) 2 (40.0)                                            |
| LSD                         | 86 (1.6) 18 (20.9)                            | 4.1 2.4 - 7.0 < 0.001                | **3.1** 1.8 - 5.5 < 0.001              | 27 (1.3) 7 (25.9)                                           |
| Amphetamine                 | 593 (10.7) 87 (14.7)                          | 3.1 2.4 - 4.0 < 0.001                | **3.0** 2.3 - 4.0 < 0.001              | 136 (6.7) 44 (32.4)                                        |
| Methamphetamine            | 186 (3.4) 21 (11.3)                           | 2.0 1.2 - 3.1 0.005                  | **2.3** 1.4 - 3.8 < 0.001              | 44 (2.2) 8 (18.2)                                           |
| Psilocybe mushrooms*        | 16 (0.3) 3 (18.8)                             | 3.5 0.98 - 12.2 0.054                | 2.2 0.60 - 8.0 0.24                    | 6 (0.3) 1 (16.7)                                           |
| SCRA                        | 26 (0.5) 4 (15.4)                             | 2.7 0.93 - 8.0 0.066                 | 1.8 0.61 - 5.4 0.29                    | 17 (0.8) 3 (17.6)                                           |
| Cannabis                    | 904 (16.4) 90 (10.0)                          | 1.9 1.5 - 2.4 < 0.001                | **1.5** 1.2 - 2.0 < 0.002              | 216 (10.6) 31 (14.4)                                       |
| Z-drugs                     | 106 (1.9) 8 (75)                              | 1.2 0.59 - 2.5 0.59                  | 1.4 0.68 - 3.1 0.34                    | 16 (0.8) -                                                  |
| Fentanyl                    | 47 (0.9) 4 (8.5)                              | 1.4 0.50 - 3.9 0.53                  | 1.3 0.44 - 3.9 0.64                    | 10 (0.5) 2 (20.0)                                          |
| Tramadol                    | 34 (0.6) 3 (8.8)                              | 1.4 0.44 - 4.7 0.55                  | 1.3 0.39 - 4.7 0.64                    | 5 (0.2) 1 (20.0)                                           |
| Crack                       | 136 (2.5) 6 (44)                              | 0.68 0.30 - 1.6 0.36                 | 1.1 0.45 - 2.5 0.89                    | 24 (1.2) 3 (12.5)                                          |
| Cocaine                     | 957 (17.3) 56 (5.9)                           | 0.91 0.68 - 1.2 0.54                  | 0.93 0.68 - 1.3 0.65                    | 164 (8.1) 11 (6.7)                                         |
| Pregabalin                  | 79 (1.4) 4 (5.1)                              | 0.79 0.29 - 2.2 0.65                  | 0.92 0.31 - 2.8 0.88                    | 3 (0.1) -                                                  |
| Mephedrone                  | 245 (4.4) 14 (57)                             | 0.90 0.52 - 1.6 0.70                  | 0.90 0.50 - 1.6 0.72                    | 72 (3.5) 4 (5.6)                                           |
| Buprenorphine               | 89 (1.6) 6 (6.7)                              | 1.1 0.47 - 2.5 0.86                  | 0.90 0.36 - 2.2 0.82                    | 16 (0.8) 1 (6.3)                                           |
| Ketamine                    | 128 (2.3) 5 (39)                              | 0.60 0.24 - 1.5 0.27                  | 0.59 0.23 - 1.5 0.26                    | 12 (0.6) -                                                  |
| MDMA                        | 461 (8.3) 20 (43)                             | 0.66 0.41 - 1.0 0.073                | **0.58** 0.36 - 0.95 0.030              | 59 (2.9) -                                                  |
| Benzodiazepines             | 1011 (18.3) 34 (34.4)                         | 0.47 0.33 - 0.67 < 0.001             | **0.53** 0.36 - 0.78 0.001             | 79 (3.9) 2 (2.5)                                           |
| Methedrone                  | 92 (1.7) 3 (33)                               | 0.50 0.16 - 1.6 0.24                  | 0.49 0.15 - 1.6 0.24                    | 21 (1.0) 1 (4.8)                                           |
| GHB/GBL                     | 710 (12.8) 25 (35)                            | 0.51 0.34 - 0.77 0.001               | **0.38** 0.25 - 0.59 < 0.001           | 215 (10.6) 4 (1.9)                                         |
| Methadone                   | 248 (4.5) 6 (24)                              | 0.36 0.16 - 0.81 0.014               | **0.34** 0.14 - 0.80 0.014             | 38 (1.9) 1 (2.6)                                           |
| Heroin                      | 1344 (24.3) 21 (16)                           | 0.19 0.12 - 0.29 < 0.001             | **0.18** 0.11 - 0.28 < 0.001           | 564 (27.8) 8 (1.4)                                         |
| Other cathinones             | 20 (0.4) 4 (20.0)                             | 3.8 1.2 - 11.3 0.019                 | 3.0 0.97 - 9.4 0.057                    | 10 (0.5) 1 (10.0)                                          |
| Other amphetamine derivatives| 27 (0.5) 4 (14.8)                             | 2.6 0.90 - 7.6 0.078                 | 1.8 0.57 - 5.5 0.33                    | 4 (0.2) 2 (50.0)                                           |
| Other stimulants            | 36 (0.7) 5 (13.9)                             | 2.4 0.94 - 6.4 0.068                 | 2.0 0.75 - 5.3 0.17                    | 8 (0.4) 3 (37.5)                                           |
| Other hallucinogens         | 55 (1.0) 8 (14.5)                             | 2.6 1.2 - 5.5 0.015                  | **2.3** 1.0 - 5.1 0.040                | 20 (1.0) 3 (15.0)                                          |
| Ethanol*                    | 2145 (38.8) 105 (4.9)                         | 0.66 0.53 - 0.84 < 0.001             | **0.54** 0.42 - 0.69 < 0.001           | -                                                          |
| Other opioids               | 204 (3.7) 5 (25)                              | 0.36 0.15 - 0.89 0.031               | **0.30** 0.12 - 0.75 0.010             | 51 (2.5) -                                                  |
| Total                       | 5529 (100) 348 (6.3)                          |                                      |                                        | 2030 (100) 159 (7.8)                                       |

Adjusted odds ratios with p < 0.05 are given in bold types
CI: confidence interval
GHB: gamma-hydroxybutyrate
LSD: lysergic acid diethylamide
MDMA: methylenedioxymethamphetamine
MDPV: methylenedioxypirovalerone
NPS: novel psychoactive substances
SCRA: Synthetic cannabinoid receptor agonists
*Includes three presentations reporting psilocybin
Ethanol only included as co-ingestion
%Percentages do not add up to 100 as in several cases more than one drug was reported

Psychosis induced by substance use is, until it has resolved, difficult to distinguish clinically from schizophrenic psychosis [31, 32]. Some authors have questioned whether they are separate entities at all [2, 33–35]. Longer duration of untreated psychosis is associated with poorer outcome, though a causal relationship has not been
established [36]. However, there is evidence suggesting that early intervention, reducing the duration of untreated psychosis, could be helpful [37–39].

Cannabis, amphetamine and cocaine were the drugs most commonly involved in presentations with psychosis in our study. This is to be expected as they are commonly used in Europe [8] and carry the risk of inducing acute psychosis [2, 3, 40]. We found amphetamine more frequently associated with psychosis than cannabis and cocaine, both as a single agent and in the logistic regression analysis, confirming that psychosis is a major feature of acute amphetamine toxicity. Cannabis, but not cocaine, was significantly associated with psychosis in the logistic regression analysis.

Among the NPS, tryptamines, MDPV and SCRAs were the drugs most frequently involved in presentations with psychosis. In our study, 57.1% of patients with tryptamine poisoning presented with psychosis, a larger proportion than the 23.6% reported among 55 enquiries concerning AMT in a poison centre case series in the UK [27]. This substantiates previous reports noting psychosis as a prominent clinical feature of acute tryptamine toxicity [41]. In a study of 23 patients with acute MDPV toxicity seen by medical toxicologists in the US, psychosis was reported in 8.7% [28]. This is less than the 27.3% in our study, and our findings are more in keeping with a US poison centre study of 236 cases of MDPV toxicity, where 36% had paranoia, 34% confusion and 40% hallucinations [18]. In our study, 15.4% of those presenting with acute SCRA toxicity had psychosis – this is comparable to the 9-11% reporting hallucinations and delusion to US poison centres in two case series of 1353 and 418 acute SCRA exposures [23, 24]. However, a German case series of 29 ED presentations with laboratory confirmed acute SCRA toxicity reported only one case of acute psychosis though 38% of the patients had hallucinations or changes of perception [42].

For mephedrone, 5.7% of patients in our study presented with psychosis, slightly less than the 8% reported among 488 enquiries to UK poison centres [27] and the 9% with paranoia and hallucinations among 57 presentations to the ED in a Scottish case series [43]. No psychotic features were reported among seven cases with laboratory confirmed mephedrone toxicity in a London ED [44].

Psychosis has previously been reported as a feature of acute methylphenidate toxicity as well as a potential side effect of methylphenidate treatment [45]. In our study, 23.1% of presentations involving methylphenidate had psychosis.

Tramadol and fentanyl differed from the other opioids, with a larger proportion of presentations with psychosis. Though only seven cases with psychosis were seen involving these drugs, two were single agent cases with fentanyl and one with tramadol. We have only found one previous report of psychosis as a clinical feature of tramadol toxicity [46], and none involving fentanyl.

In addition to the risk of inducing acute psychosis, regular use of several recreational drugs, especially amphetamine, methamphetamine and cannabis, has been shown to be associated with later development of chronic psychosis or schizophrenia [2, 11, 34, 47]. Japanese studies have reported schizophrenia-like psychosis in methamphetamine users persisting for months to years after discontinuation of methamphetamine use [11, 33]. A large cohort study in California found an increased risk of later being diagnosed with schizophrenia in previously non-psychotic hospitalised users of methamphetamine or cannabis [34]. A meta-analysis of seven studies found cannabis use to be an independent risk factor for later development of chronic psychosis [47]. The risk was higher the more cannabis was used, and the earlier in life the start of the exposure [47]. It also seems that patients with previous substance use associated psychosis are at greater risk of subsequent psychotic episodes [2, 33].

Limitations
Data on previous psychiatric diagnoses were not collected. Therefore, we are not able to determine whether the psychosis seen at the time of the acute recreational drug toxicity presentation was an acute psychosis, the patient’s regular psychotic state or an exacerbation of a chronic psychosis. Furthermore, we did not collect information on the frequency or duration of drug use. It is possible that large proportions of presentations with psychosis reflect drugs of choice for patients with chronic psychosis [48]. We do not have any follow-up data for the patients in our study. However, the short length of stay and high proportion of patients medically discharged from the ED suggests that in a substantial proportion the psychosis was of limited duration.

The diagnosis of psychosis was made by the treating ED clinician, and not necessarily by a psychiatrist. Consequently, there is a potential for misdiagnosis; although this represents routine clinical practice and assessment/management of patients in European EDs with acute recreational drug toxicity. There may also be inconsistencies in the diagnosis of psychosis across countries. This may possibly contribute to the variation of psychosis rates between centres seen in our material. The diagnosis of psychosis was mainly based on the assessment of the clinician treating the patient. Therefore, some inter-rater variability must be expected. On the other hand, our results are based on decisions made in real clinical situations, strengthening their generalizability.
Drug(s) involved in the presentations were based on patient self-report. Patients may not report all drugs ingested, and may not know the actual psychoactive ingredient in the substance(s) taken. There is the potential that this will lead to some misclassification. However, this reflects the actual clinical situation in most settings treating acute poisoning, as well as current best practice in toxicology, in which patients are managed based on their clinical presentation.

The proportion of presentations with psychosis is not a measure of a drug’s potential to induce psychosis. Rather, it is a measure of to what extent psychosis is part of the problems associated with the drug’s acute toxicity. For many drugs the numbers in our study are small, and for these drugs the results should be interpreted with caution.

Conclusions

There is considerable variation between drugs in how commonly psychosis is a feature of acute recreational drug toxicity. Psychosis was seen in a large proportion of presentations with acute amphetamine toxicity. Amongst the NPS, although numbers were small, psychosis was rare in methedrone and methedrone poisoning, but occurred frequently with tryptamines, MDPV and the synthetic cannabinoid receptor agonists; psychosis was also common in presentations involving methylphenidate.

In rapidly changing drug markets, the Euro-DEN sentinel network contributes to measuring the scale of drug-related harms in Europe beyond other more established European indicators [49–51]. Further study is required in larger cohorts to understand the associations found and consider other factors such as the importance of underlying psychiatric co-morbidity. However, in this series, psychosis was seen in a significant minority of presentations and this has important implications for prevention, follow-up and referral for further treatment, and represents an important burden on health services.

Acknowledgement

Euro-DEN Research Group - Corporate Author: Jacek Sein Anand, Alan Blake, Lucie Chevillard, Florian Eyer, Miguel Galicia, Catarina Homar, Gesche Jürgens, E. Laiakoni, M.E. Liechti, Gerard Markey, Bruno Mégarbane, Oscar Miro, Adrian Moughty, Niall O’Connor, Raido Paasma, Carsten Boe Pedersen, Kristiina Pöld, Jordi Puiguriguera, Rounen Sedefov, Jochen Stenzel, Wojciech Waldman, W Stephen Waring.

Funding

The Euro-DEN Project was funded by the DRIIP/SEC Programme of the European Union; all of the authors had funding from the European Commission through the Euro-DEN project except MEL and EL whose costs were co-funded by the Swiss Centre of Applied Human Toxicology, RS and IG whose costs were funded by the European Monitoring Centre for Drugs and Drug Addiction, and KP.

Availability of data and materials

Data are not available for sharing. Several manuscripts based on Euro-DEN data are in preparation.

Authors’ contribution

PD, DW, AD, IG, KEH, FH, CY and OMV designed the study. The Euro-DEN research group contributed to developing the design. All authors including the Euro-DEN research group, except IG and RS, collected data. AD collated the data. OMV analysed the data and drafted the manuscript. All authors including the Euro-DEN research group revised the manuscript and approved the final version.

Competing interests

PD and DW work with the European Monitoring Centre for Drugs and Drug Addiction and the UK Advisory Council for the Misuse of Drugs.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Patient consent was not required as the data collated for Euro-DEN was collected as part of routine clinical care; individual Euro-DEN centres obtained appropriate local ethical approval for data collation [51].

Author details

1Department of General Practice, University of Oslo, Oslo, Norway. 2Oslo Accident and Emergency Outpatient Clinic, City of Oslo Health Agency, Oslo, Norway. 3Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK. 4Clinical Toxicology, Faculty of Life Sciences and Medicine, King’s College London, London, London, UK. 5Emergency Department and Clinical Toxicology Unit, Hospital Universitari Son Espases, Mallorca, Spain. 6The Norwegian CBRNe Centre of Medicine, Oslo University Hospital, Oslo, Norway. 7European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.

Received: 9 February 2016 Accepted: 13 August 2016
Published online: 18 August 2016

References

1. Byrne P. Managing the acute psychotic episode. BMJ. 2007;334:686–92.
2. Brämmers JG, Gundersen OH, Gutermann J, Rognli EB, Konstenius M, Lobberg EW, et al. Amphetamine-induced psychosis—a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221.
3. Roncero C, Daigre C, Grau-Lopez L, Barral C, Perez-Pazos J, Martinez-Luna N, et al. An international perspective and review of cocaine-induced psychosis: a call to action. Subst Abuse. 2014;35:321–7.
4. Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: a comparison across substances. Comp Psychiatry. 2009;50:495–50.
5. Brugha T, Singleton N, Melzer H, Bebbington P, Farrell M, Jenkins R, et al. Psychosis in the community and in prisons: a report from the British National Survey of psychiatric morbidity. Am J Psychiatry. 2005;162:774–80.
6. Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46:735–52.
7. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2011;56:1209–17.
8. European monitoring centre for drugs and drug addiction (EMCDDA). European Drug Report 2015. Trends and developments. Lisbon: EMCDDA; 2015.
9. Europol and European monitoring centre for drugs and drug addiction (EMCDDA). EU drug markets report: a strategic analysis. Luxembourg: Publications office of the European Union; 2013.
10. Xi Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Ronomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry. 2015;2:233–8.
11. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand. 1994;89:428–32.
12. Faishpour B, Molasvi S, Shahat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013;22:341–9.
13. Arendt M, Rosenberg R, Foldager L, Porto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 335 incident cases. Br J Psychiatry. 2005;187:50–10.
14. United Nations Office on Drugs and Crime (UNODC). The challenge of new psychoactive substances: a report from the global SMART programme. Vienna: UNODC; 2013.
15. Hill SL, Thomas SH. Clinical Toxicology of newer recreational drugs. Clin Toxicol. 2011;49:705–19.
16. Wood DM, Greene SL, Dargan PI. Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. Eur J Emerg Med. 2013;20:263–7.
17. Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int. 2014;111:139–47.
18. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol. 2011;49:499–505.
19. Castaneto MG, Gorelick DA, Desrosiers NA, Hartman RL, Pirat S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
20. Chan WL, Wood DM, Hudson S, Dargan PI. Acute psychosis associated with recreational use of benzofuran 6-2-aminopropanoylbenzofuran (6-APB) and cannab. J Med Toxicol. 2013;9(3):278–81.
21. Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, et al. “Spice psychosis”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28:379–89.
22. Wood DM, Dargan PI. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clin Toxicol. 2012;50:277–32.
23. Hoyte CD, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoids exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60:435–8.
24. Forrestér MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31:1006–11.
25. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J. 2011;28:866–9.
26. Kamour A, James D, Lupton DJ, Cooper G, Eddleston M, Vale A, et al. Patterns of presentation and clinical features of toxicity after reported use of (2-aminopropanoyl)-2,3-dihydrobenzofurans, the ‘benzofuran’ compounds. A report from the United Kingdom National Poisons Information Service. Clin Toxicol. 2014;52:1025–31.
27. Kamour A, James D, Spears R, Cooper G, Lupton DJ, Eddleston M, et al. Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK national poison information service. Clin Toxicol. 2014;52:192–7.
28. Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engelsreten KM, et al. Acute methylenedioxymethamphetamine toxicity. J Med Toxicol. 2015;11:185–94.
29. Wood DM, Heyerdahl F, Yates CB, Dines AM, Giraudon I, Hovda KE, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2014;52:239–41.
30. Sergeant ESG. Epitools epidemiological calculators. AusVet Animal Health Services and Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease. 2016. http://epitools.ausvet.com.au. Accessed 8 Jan 2016.
31. Medhus S, Mordal J, Holm B, Morland J, Bramness JG. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013;206:17–21.
32. Srisurapanont M, Arunpongpaisal S, Wada K, Mardsen J, Ali R, Kongsakorn R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Progr Neuropsychopharmacol Biol Psychiatry. 2011;35:959–64.
33. Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 2000;914:1–12.
34. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169:389–96.
35. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry. 2008;69:358–67.
36. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975–83.
37. Marshall M, Rathbone J. Early intervention for psychosis. Schizophr Bull. 2011;37:1111–4.
38. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346:f185.
39. Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:74–80.
40. D’Souza DC, Perry E, MacDougall L, Ammenmann Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558–72.
41. Greene SL. Tryptamines. In: Dargan PI, Wood DM, editors. Novel psychoactive substances: classification, pharmacology and toxicology. London: Academic press; 2013. p. 363–81.
42. Hermanns-Clausen M, Knesel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabionoids: clinical and laboratory findings. Addiction. 2013;108:534–44.
43. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J. 2011;28:1055–8.
44. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol. 2010;48:924–7.
45. Kraemer M, Uekermann J, Wittfang J, Kiri B. Mephedrone-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33:204–6.
46. Chen KL, Lu ML, Shen WW. Tranadol-related psychosis in a patient with bipolar I disorder, Acta Neuropsychiatr. 2015;27:126–8.
47. Seiple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:837–94.
48. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev. 2007;27:494–510.
49. European monitoring centre for drugs and drug addiction (EMCDDA). Key epidemiological indicators. http://www.emcdda.europa.eu/europes/key-indicators. Accessed 9 Sept 2015.
50. Heyerdahl F, Hovda KE, Giraudon I, Yates CB, Dines AM, Sedefov R, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol. 2014;52:1005–12.
51. Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53:893–900.